AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03862066 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: 5 milliliters (mL) of blood will be collected at the time of surgery
Study NCT03862066 — intervention group
Intervention type: OTHER
Intervention: Tissue collection
Description: Left over tissue will be collected at the time of surgery
Study NCT02317614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SteadyRx
Description: The proposed intervention consists of four core elements. The intervention will include a Smartphone application that allows direct interaction with the SteadyRx system, as well as automatic events controlled via a central server. The CONSULT element will facilitate patient-provider communication with links to care providers and other care resources. The REMIND element will provide telephonic reminders for late doses. The OBSERVE element will feature electronically observed dosing through time-stamped video recordings made on the Smartphone and sent securely to a central server. The REWARD element will feature monetary incentives designed to reinforce short- and long-term medication adherence and promote reductions in viral load.
Study NCT05937828 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: description of the long-term health of adult patients, identification of the heterogenous genetic underlying pathophysiologic contexts, study of the benefit-risk balance of treatments, including the growing development of targeted therapies.
Study NCT00631449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily, in addition to continuing to take their current anti-HIV medicines.
Study NCT00631449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
Study NCT01777360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALAIR, radiofrequency catheter for bronchial THERMOPLASTY
Description: radiofrequency catheter for bronchial THERMOPLASTY
Study NCT01108406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonitus SoundBite System
Description: Non Surgical Bone Conduction Device
Study NCT01108406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoundBite Hearing System
Study NCT03301623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: The CDS intervention will test the use of existing guideline-based EHR alerts related to the prescription of opioids. CDS alerts employ computer algorithms that account for patient characteristics and diagnoses to deliver reminders of appropriate use when a provider enters an order for a medication.
Study NCT03301623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education and Activation Tools
Description: The patient education materials selected for this study: Pain Management: Which Treatment is Right for You, Preparing for Your Health Care Visit, and a video from the American Chronic Pain Association (ACPA) named A Car with Four Flat Tires, which helps to give patients a better understanding of how multi-modal treatment can be more effective than relying on one source of treatment (e.g., pain medication).
Study NCT02981303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
Study NCT02981303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
Study NCT00266396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommend full weight-bearing
Description: The full weight-bearing group is trained in 4-point gait with crutches and is recommended to put as much weight as tolerated on the leg on which surgery has been performed, immediately after surgery
Study NCT00266396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommend parital weight-bearing
Description: The partial weight-bearing group is trained in 3-point gait with crutches and is instructed to limit weight-bearing of the affected leg to 20kg for a period of six-weeks. Scales are used to train these participants not to exceed 20kg
Study NCT01675661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
Study NCT01675661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
Study NCT04628520 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
Study NCT04628520 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen matrix
Description: After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
Study NCT04628520 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance
Description: Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy
Study NCT04628520 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Maintenance
Description: Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy
Study NCT03113617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT02279693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CBCT
Description: 10 participants will receive a cone beam computed tomography (CBCT) repositioning
Study NCT02279693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fiducial marker (kV imaging)
Description: 10 participants will receive a kV imaging of fiducial marker repositioning.
Study NCT02279693 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: IGRT Associated With IMRT
Study NCT03113617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
Description: Given IV
Study NCT03113617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03113617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT00562575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLx-4090
Study NCT00562575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01429116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
Study NCT00943267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alpha
Description: Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0
Study NCT00943267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0.9%)
Description: Normal saline is given intrabronchially by bronchoscopy at t=0
Study NCT00943267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
Study NCT00943267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin
Description: Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
Study NCT00943267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)
Study NCT00943267 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bronchoscopy
Description: Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)
Study NCT00943267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling is done by venapuncture at t=0 and t=6
Study NCT00943267 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling is done by venapuncture at t=0 and t=6
Study NCT04545060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)
Study NCT03723941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin plus Etoposide
Description: Etoposide 100 mg/m2 will be administered IV on days 1, 2, 3 diluted in 500 mL of isotonic NaCl or 5% dextrose.~Cisplatin, 80 mg/m2 will be administered IV on day 1, diluted in 500 mL of isotonic NaCl.
Study NCT01191983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered by subcutaneous injection Q4W
Study NCT00749736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 4000 IU of cholecalciferol per day~15 patients will be enrolled in each arm.
Study NCT00749736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: doxercalciferol
Description: 1 mcg of doxercalciferol per day
Study NCT00749736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.~15 patients will be enrolled in each arm.
Study NCT02657733 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Radical-7
Description: Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time.~Radical-7- measures respiratory rate according to acoustic respiratory rate (RRa).
Study NCT03599830 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive test passations
Description: Tests :~MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences
Study NCT03596151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Click Device
Description: A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
Study NCT02657733 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nellcor™ Bedside Respiratory Patient Monitoring System
Description: Comparison between 3 different monitors that measure repiratory rate. The participant is connected to 3 monitors at the same time.~Nellcor™ Bedside Respiratory Patient Monitoring System - measures respiratory rate according to oximetry respiration rate (RRoxi).
Study NCT02657733 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Capnostream 20p
Description: Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream 20p- measures respiratory rate according to Capnography (RRetco2).
Study NCT02290470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: * Drug: Olanzapine 10 mg oral~* Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~* Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy).
Study NCT03258073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical simulation using scenario execution
Description: Each team of students will be exposed to simulation two times in a semester totaling to four times a year. In a scenario execution, participants are placed in a simulated experience of a medical emergency. Participants are required to respond and their reactions are observed by the investigators. After the experience, participants will have a debriefing session to learn from their experience of handling this emergency.
Study NCT00328016 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Guided Breathing
Description: The participant will engage in daily 15 min sessions of meditative relaxation that involves quiet attention to breathing pattern with no attempt to manipulate breathing pattern
Study NCT00328016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESPeRATE
Description: The participant will be trained to perform a guided breathing task that involves a chest expansion sensor, battery-powered microcomputer, and earphones
Study NCT02835781 — intervention group
Intervention type: OTHER
Intervention: Acellular dermal matrix implantation
Description: Acellular dermal matrix obtained from Central tissue bank, University Hospital Bratislava, will be used for acellular dermal matrix implantation.
Study NCT04053686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaks
Description: 3-min breaks every half hour at work
Study NCT00627315 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric bypass
Description: NOTE: Surgery will not be paid by the study
Study NCT00627315 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric banding
Description: NOTE: Surgery will not be paid by the study
Study NCT02781870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LiquiBand Fix8 glue fixation
Description: Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
Study NCT02781870 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: No-fixation
Description: Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible without glue fixation.
Study NCT05710939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Study NCT02402114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 120 mg Hydrocortisone given orally one time.
Study NCT03723941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation or Mitotane
Description: Observation or mitotane alone according to the investigator's preference
Study NCT02290470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: * Drug: Olanzapine 10 mg oral~* Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~* Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy).
Study NCT02290470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine
Description: all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
Study NCT02290470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine
Description: all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
Study NCT03723941 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation or Mitotane
Description: Observation or mitotane alone according to the investigator's preference
Study NCT01675999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative simplified FOLFOX-4 chemotherapy
Description: Preoperative chemotherapy
Study NCT01675999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative FOLFOX4+Cetuximab chemotherapy
Description: Preoperative chemotherapy
Study NCT01675999 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surgery followed by FOLFOX4 chemotherapy
Description: Preoperative chemotherapy
Study NCT03795623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voice-Weaning
Description: Audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
Study NCT03795623 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Muted audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
Study NCT02858284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TUG
Description: Therapeutic Ultrasound for Glaucoma
Study NCT02858284 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Study NCT04679558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish added to the preventive protocol
Description: Antibacterial agent varnish added to the preventive protocol
Study NCT04679558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preventive protocol
Description: Preventive protocol
Study NCT00879983 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: azithromycin (Zithromax)
Description: 1. a single dose of azithromycin ER 2g~2. 3-day regimen of azithromycin tablet 500mg
Study NCT00879983 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: azithromycin (Zithromax)
Description: 1. 3-day regimen of azithromycin tablet 500mg~2. a single dose of azithromycin ER 2g
Study NCT03079245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education Plus (E+)
Description: Education Plus was an intervention developed by the study team based on the Center for Disease Control (CDC) 12 Step Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. The study team provided Education Plus quarterly to prescribers at the three sites (NICU A, B, C) randomized to this intervention. Examples of topics presented were an overview of antimicrobial stewardship principles, epidemiology of healthcare-associated infections (HAIs), prevention of surgical site infections, antimicrobial susceptibility testing, and pharmacokinetic principles. Educational formats included didactic lectures, participation via the audience response system, case vignettes, and panel discussions.
Study NCT03079245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Decision Support
Description: The CDS tool was an intervention developed in consultation with neonatologists and pediatric infectious disease physicians from NICU A and B. Algorithms for empiric and targeted antimicrobial therapy for common pathogens and common clinical scenarios using local antimicrobial susceptibility patterns were developed. The CDS tool also provided additional components to facilitate antimicrobial prescribing, e.g., patient weight, day of life, previous culture results, antimicrobial orders, and selected laboratory results including white blood cell and platelet count, C-reactive protein, creatinine, and therapeutic drug levels. NICUs A and B also received E+
Study NCT03079245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prescriber Audit and Feedback
Description: The prescriber audit and feedback (PAF) intervention was developed by the study team which held focus groups with neonatologists at NICU A (the site randomized to this intervention) to determine the feedback parameters and feedback format as previously described. Neonatologists at NICU A were provided aggregated prescribing data bimonthly that described inappropriate use as described below and prolonged therapy (>7 days) for culture-negative late onset sepsis. NICU A also received CDS and E+.
Study NCT01282567 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: The study will be proposed to four patients hospitalized in the Diabetes Unit for a glucidic fast test carried out during 24 hours (lunch, dinner and breakfast). Blood samples will be taken every 20 minutes during 6 hours and 40 minutes to measure plasma insulin concentration and blood glucose. T0 will correspond to the first modification of the insulin basal flow (in more or less) or to the first insulin bolus corrector, usually administered if capillary blood glucose reaches 1.8 g/l. The capillary blood glucose monitoring will be performed every two hours by the nurse.